Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis

Background: Examining the effect of antibiotic resistance, use of intravitreal antibiotics and systemic corticosteroids on visual outcome of eyes with acute endophthalmitis. Methods: We included 226 eyes with acute endophthalmitis, treated using a standardized protocol. Visual outcome up to 12 month...

Full description

Bibliographic Details
Main Authors: Xia-Ni Wu, Yi-Hsing Chen, Lazha Sharief, Ahmed Al-Janabi, Nura Al Qassimi, Sue Lightman, Oren Tomkins-Netzer
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/11/7/843
Description
Summary:Background: Examining the effect of antibiotic resistance, use of intravitreal antibiotics and systemic corticosteroids on visual outcome of eyes with acute endophthalmitis. Methods: We included 226 eyes with acute endophthalmitis, treated using a standardized protocol. Visual outcome up to 12 months was assessed related to biopsy results, antibiotics resistance and treatment regimens. Results: Vitreous biopsies were more likely to be culture-positive (41.1%) than anterior chamber biopsies (21.6%, <i>p</i> < 0.0001). Antibiotic resistance for amikacin was found in 19 eyes (24.7%), vancomycin in 29 eyes (31.5%) and moxiflocacin in 14 eyes (16.1%). At presentation 91.53% of eyes had BCVA < 20/40, reducing by 1 month to 69.94% (<i>p</i> < 0.0001) and remaining stable at 12 months. There was no difference in visual outcome for those receiving early systemic corticosteroids. Endophthalmitis following cataract surgery (OR 1.66, 1.04–2.66 95% CI, <i>p</i> = 0.03) and receiving intravitreal vancomycin (OR 3.15, 1.18–8.42 95% CI, <i>p</i> = 0.02) were associated with a greater chance of final BCVA ≥ 20/40. Conclusion: Using vitreous taps with intravitreal antibiotics, despite an increase in resistance to both vancomycin and moxifloxacin, results in a final BCVA > 20/200 in half of eyes and ≥20/40 in a third. Early treatment with intravitreal antibiotics should not be delayed.
ISSN:2079-6382